CHICAGO — Continuous subcutaneous apomorphine infusion reduced “off” time and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease in the United ...

The FDA has approved Onapgo (apomorphine hydrochloride) for the treatment of motor fluctuations in adults with advanced Parkinson disease.

The FDA has accepted the resubmitted NDA for SPN-830, an apomorphine infusion device for the continuous motor fluctuation Tx in Parkinson.

Onapgo is the first and only wearable subcutaneous apomorphine infusion device that provides continuous treatment during the waking day, offering patients more consistent control of motor ...

Treatment with APO-go ® /MOVAPO ® (apomorphine) subcutaneous infusion for 12 weeks gave significantly greater reductions in OFF time (periods when PD medications don't work) from baseline ...

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA PRESS RELEASE GlobeNewswire Nov. 2, 2023, 07:00 AM ...

Continuous subcutaneous apomorphine infusion has a proven 30-year history in Europe, bolstering confidence in ONAPGO's potential success.

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA Published Aug 19, 2024 7:00am EDT ...

Supernus recently submitted its NDA for its Apomorphine Infusion Pump, or SPN-830, with putative launch in H2, 2021.